Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease - Top-Institutions - MDSpire

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

  • By

  • Vasantharaja Raguraman

  • Miranda Mysinger

  • Mohit Verma

  • Shanid Mohiyuddin

  • Nashwan Jabbour

  • Melissa Kesler

  • Trupti Joshi

  • Senthilnathan Palaniyandi

  • Gerhard C. Hildebrandt

  • June 11, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Fred Hutch Cancer Center
    Fred Hutch Cancer Center

    Seattle, Washington

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    The Ohio State University College of Medicine
    The Ohio State University College of Medicine

    Columbus, Ohio

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    Willamette Valley Cancer Institute
    Willamette Valley Cancer Institute

    Eugene, Oregon

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

  • by Vasantharaja Raguraman, Miranda Mysinger, Mohit Verma, Shanid Mohiyuddin, Nashwan Jabbour, Melissa Kesler, Trupti Joshi, Senthilnathan Palaniyandi, Gerhard C. Hildebrandt

  • June 11, 2026

Related Content

Case Report: Post-transplant lymphoproliferative disorder mimicking Baló’s concentric sclerosis

Correction: Exploring the prognostic value of combined assessment of bone marrow plasma cell morphology, Vitamin D, and interleukin-6 in multiple myeloma

Peripheral B cell immune dysregulation genetically contributes to stage-dependent neuroinflammation and identifies priority therapeutic targets in Parkinson’s disease: a computational integration of Mendelian randomization and single-cell transcriptomics